Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Author information

  • 1Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA. jengelman@partners.org

Abstract

There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.

PMID:
19629070
DOI:
10.1038/nrc2664
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center